# Isabelle Ayoub

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/isabelle-ayoub/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,718 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 25 |
| i10-index | 39 |
| Last Known Institution | The Ohio State University |
| OpenAlex ID | https://openalex.org/A5070696987 |
| ORCID iD | 0000-0002-7988-3082 |
| Works | 115 |

## Researcher papers

- [KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS](https://scholariq.org/papers/kdigo-2024-clinical-practice-guideline-for-the-management-of-lupus-nephritis/)
- [Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-1-conclusions-from-a-kidney/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-2-conclusions-from-a-kidney/)
- [CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease](https://scholariq.org/papers/curegn-study-rationale-design-and-methods-establishing-a-large-prospective/)
- [Staphylococcus Infection–Associated GN – Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort](https://scholariq.org/papers/staphylococcus-infection-associated-gn-spectrum-of-iga-staining-and-prevalence/)
- [Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19](https://scholariq.org/papers/multivesicular-bodies-mimicking-sars-cov-2-in-patients-without-covid-19/)
- [Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis](https://scholariq.org/papers/executive-summary-of-the-kdigo-2024-clinical-practice-guideline-for-the/)
- [The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug](https://scholariq.org/papers/the-use-of-glucocorticoids-in-lupus-nephritis-new-pathways-for-an-old-drug/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

## Researcher university

- [The Ohio State University](https://scholariq.org/institutions/the-ohio-state-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.